Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Queen Mary University of London · William Harvey Research Institute · +41 more institutions
Abstract
Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue. Approximately 40% of patients do not respond to individual biologic therapies and 5-20% are refractory to all. In a biopsy-based, precision-medicine, randomized clinical trial in RA (R4RA; n = 164), patients with low/absent synovial B cell molecular signature had a lower response to rituximab (anti-CD20 monoclonal antibody) compared with that to tocilizumab (anti-IL6R monoclonal antibody) although the exact mechanisms of response/nonresponse remain to be established. Here, in-depth histological/molecular analyses of R4RA synovial biopsies identify…
Citation impact
- FWCI
- 38.31
- Percentile
- 100%
- References
- 60
Authors
68- FRFelice RivelleseCorresponding
Queen Mary University of London, William Harvey Research Institute
- AEAnna E. A. Surace
Queen Mary University of London, William Harvey Research Institute
- KGKatriona Goldmann
Queen Mary University of London, William Harvey Research Institute
- ESElisabetta Sciacca
Queen Mary University of London, William Harvey Research Institute
- CÇCankut Çubuk
Queen Mary University of London, William Harvey Research Institute
Topics & keywords
- Rituximab
- Tocilizumab
- Medicine
- Rheumatoid arthritis
- Biomarker
- Internal medicine
- Clinical trial
- Biopsy
- Good health and well-being